Dyadic International (NASDAQ:DYAI) & Celularity (NASDAQ:CELU) Head-To-Head Comparison
by Tristan Rich · The Markets DailyDyadic International (NASDAQ:DYAI – Get Free Report) and Celularity (NASDAQ:CELU – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, risk, profitability, analyst recommendations and dividends.
Volatility and Risk
Dyadic International has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.
Earnings and Valuation
This table compares Dyadic International and Celularity”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dyadic International | $3.09 million | 5.38 | -$7.36 million | ($0.23) | -1.80 |
| Celularity | $26.55 million | 1.43 | -$91.72 million | ($3.33) | -0.39 |
Dyadic International has higher earnings, but lower revenue than Celularity. Dyadic International is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
27.9% of Dyadic International shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 20.9% of Dyadic International shares are held by insiders. Comparatively, 17.3% of Celularity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Dyadic International and Celularity’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dyadic International | -201.43% | -2,920.31% | -84.77% |
| Celularity | -345.45% | N/A | -77.94% |
Analyst Recommendations
This is a summary of recent ratings and price targets for Dyadic International and Celularity, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dyadic International | 1 | 0 | 1 | 0 | 2.00 |
| Celularity | 1 | 0 | 0 | 0 | 1.00 |
Dyadic International currently has a consensus price target of $3.00, indicating a potential upside of 622.89%. Given Dyadic International’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Dyadic International is more favorable than Celularity.
Summary
Dyadic International beats Celularity on 10 of the 14 factors compared between the two stocks.
About Dyadic International
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
About Celularity
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.